Biocompatibility of Thermally Hydrocarbonized Porous Silicon Nanoparticles and their Biodistribution in Rats

被引:261
作者
Bimbo, Luis M. [1 ]
Sarparanta, Mirkka [2 ]
Santos, Helder A. [1 ]
Airaksinen, Anu J. [2 ]
Makila, Ermei [3 ]
Laaksonen, Timo [1 ]
Peltonen, Leena [1 ]
Lehto, Vesa-Pekka
Hirvonen, Jouni [1 ]
Salonen, Jarno [3 ]
机构
[1] Univ Helsinki, Fac Pharm, Div Pharmaceut Technol, FI-00014 Helsinki, Finland
[2] Univ Helsinki, Dept Chem, Lab Radiochem, FI-00014 Helsinki, Finland
[3] Univ Turku, Dept Phys, Lab Ind Phys, FI-20014 Turku, Finland
基金
芬兰科学院;
关键词
porous silicon; nanoparticles; oral delivery; cytotoxicity; biodistribution; Caco-2; cells; MESOPOROUS SILICON; DRUG-DELIVERY; SURFACE-CHEMISTRY; PARTICLES; MICROPARTICLES; SIZE; CYTOTOXICITY; INTERNALIZATION; RELEASE; MODEL;
D O I
10.1021/nn901657w
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Porous silicon (PSI) particles have been studied for the effects they elicit in Caco-2 and RAW 264.7 macrophage cells in terms of toxicity, oxidative stress, and inflammatory response. The most suitable particles were then functionalized with a novel F-18 label to assess their biodistribution after enteral and parenteral administration in a rat model. The results show that thermally hydrocarbonized porous silicon (THCPSi) nanoparticles did not induce any significant toxicity, oxidative stress, or inflammatory response in Caco-2 and RAW 264.7 macrophage cells. Fluorescently labeled nanoparticles were associated with the cells surface but were not extensively internalized. Biodistribution studies in rats using novel F-18-labeled THCPSi nanoparticles demonstrated that the particles passed intact through the gastrointestinal tract after oral administration and were also not absorbed from a subcutaneous deposit. After intravenous administration, the particles were found mainly in the liver and spleen, indicating rapid removal from the circulation. Overall, these silicon-based nanosystems exhibit excellent in vivo stability, low cytotoxicity, and nonimmunogenic profiles, ideal for oral drug delivery purposes.
引用
收藏
页码:3023 / 3032
页数:10
相关论文
共 40 条
[1]   Porous silicon in drug delivery devices and materials [J].
Anglin, Emily J. ;
Cheng, Lingyun ;
Freeman, William R. ;
Sailor, Michael J. .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (11) :1266-1277
[2]   Cytotoxicity and Genotoxicity of Silver Nanoparticles in Human Cells [J].
AshaRani, P. V. ;
Mun, Grace Low Kah ;
Hande, Manoor Prakash ;
Valiyaveettil, Suresh .
ACS NANO, 2009, 3 (02) :279-290
[3]   Design of silicon-based misonidazole analogues and 18F-radiolabelling [J].
Bohn, Pierre ;
Deyine, Abdallah ;
Azzouz, Rabah ;
Bailly, Laetitia ;
Fiol-Petit, Catherine ;
Bischoff, Laurent ;
Fruit, Corinne ;
Marsais, Francis ;
Vera, Pierre .
NUCLEAR MEDICINE AND BIOLOGY, 2009, 36 (08) :895-905
[4]   Ideal passivation of luminescent porous silicon by thermal, noncatalytic reaction with alkenes and aldehydes [J].
Boukherroub, R ;
Morin, S ;
Wayner, DDM ;
Bensebaa, F ;
Sproule, GI ;
Baribeau, JM ;
Lockwood, DJ .
CHEMISTRY OF MATERIALS, 2001, 13 (06) :2002-2011
[5]  
Brayden David J., 2003, Drug Discovery Today, V8, P976, DOI 10.1016/S1359-6446(03)02874-5
[6]   Chemistry with [18F]fluoride ion [J].
Cai, Lisheng ;
Lu, Shuiyu ;
Pike, Victor W. .
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2008, 2008 (17) :2853-2873
[7]   Bioactive silicon structure fabrication through nanoetching techniques [J].
Canham, LT .
ADVANCED MATERIALS, 1995, 7 (12) :1033-+
[8]  
Chapekar MS, 1996, J BIOMED MATER RES, V31, P251, DOI 10.1002/(SICI)1097-4636(199606)31:2<251::AID-JBM12>3.0.CO
[9]  
2-O
[10]  
CHARKES ND, 1979, J NUCL MED, V20, P1150